- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
London Today
By the People, for the People
Ozempic-Style Drugs May Slash Heart Attack Complication Risks
New research suggests GLP-1 medications could prevent deadly 'no-reflow' condition after heart attacks.
Published on Mar. 6, 2026
Got story updates? Submit your updates here. ›
A study published in Nature Communications found that a class of weight-loss drugs that mimic the hormone GLP-1 may prevent a dangerous complication called 'no-reflow' in nearly half of heart attack patients. The research identified a brain-gut-heart signaling pathway that allows the drugs to open narrowed capillaries in the heart, improving blood flow and reducing the risk of heart failure and death.
Why it matters
Heart attacks often leave behind microscopic blood vessel damage that restricts blood flow, increasing the risk of life-threatening complications. If proven effective in humans, these GLP-1 drugs could become an important new emergency treatment to minimize heart tissue damage and improve outcomes for heart attack patients.
The details
The study, led by researchers at the University of Bristol and University College London, found that when GLP-1 is released in the gut or administered as a drug, it sends a signal to the brain that then triggers the opening of potassium channels in cells called pericytes. This allows the small blood vessels (capillaries) to widen and improve blood flow to the heart muscle. When the researchers removed the potassium channels, the drugs no longer provided this protective effect.
- The study was published this week in the journal Nature Communications.
The players
Dr. Svetlana Mastitskaya
The lead author of the study and a senior lecturer at Bristol Medical School.
University of Bristol
The institution where the lead researcher is based and where the study was conducted.
University College London
The other institution involved in the research.
British Heart Foundation
The primary funder of the research.
What they’re saying
“In nearly half of all heart attack patients, tiny blood vessels within the heart muscle remain narrowed, even after the main artery is cleared during emergency medical treatment. This results in a complication known as 'no-reflow,' where blood is unable to reach certain parts of the heart tissue.”
— Dr. Svetlana Mastitskaya, Lead author of the study (Press release)
What’s next
Clinical trials are necessary to determine whether the brain-gut-heart pathway operates with the same timing and efficacy in humans. Additionally, the study does not establish whether long-term use of the medication provides a pre-existing level of protection.
The takeaway
This research suggests that existing GLP-1 medications, already used for type 2 diabetes and obesity, could potentially be repurposed as emergency treatments to reduce tissue damage and complications after heart attacks. If proven effective, these drugs could become an important new tool in improving outcomes for heart attack patients.
